David Wallace
Executive Editor

Having previously worked in the European chemicals industry, Dave has been with Generics Bulletin since 2010. Keeping a close eye on deals, corporate strategy and market developments in the off-patent sector, he also brings his background and education in law to bear on industry litigation as well as national legislative and regulatory affairs, with a particular interest in France where he has lived and studied in the past. A regular delegate to generics and biosimilars events and conferences as well as a frequent panel moderator, he maintains close links with industry representatives around the world. He also organizes and judges the annual Global Generics & Biosimilars Awards. In his spare time, he enjoys art and playing the piano.
Latest From David Wallace
AAM Departures Lead To Change Of Chair For IGBA
The AAM has confirmed the departure of three executives, one of whom had also been serving as chair of the IGBA. As a result, the global generics industry association has brought in a new interim chair, at the same time as the head of one of the industry’s largest players has joined its CEO Advisory Committee.
‘In A Word, Complicated’ – AAM’s Burton Talks US Biosimilars
With the first US Humira rival having just hit the market and biosimilars seeing increasing adoption overall, Craig Burton – executive director of the AAM’s Biosimilars Council – tells Generics Bulletin that the US biosimilars market is “doing better, but we still have improvements to make.”
ATOM Coalition Seeks Partners To Create New Oncology Markets
The ATOM Coalition is seeking partners in the generics and biosimilars industry to help create new markets for cancer medicines in LLMICs.
AAM Departures Lead To Change Of Chair For IGBA
The AAM has confirmed the departure of three executives, one of whom had also been serving as chair of the IGBA. As a result, the global generics industry association has brought in a new interim chair, at the same time as the head of one of the industry’s largest players has joined its CEO Advisory Committee.
Hitting A Moving Target: Teva’s Dethlefs Discusses US Complex Generics
With a number of US complex generic opportunities in Teva’s pipeline, the company’s executive vice president for North America commercial, Sven Dethlefs, talks about the challenges of bringing complex products to market against a backdrop of evolving FDA requirements.
Blow For EU Tecfidera Rivals As Biogen Triumphs In Legal Battle
Developers of generic dimethyl fumarate have received a setback after a CJEU ruling in Biogen’s favor gave Tecfidera EU regulatory marketing protection until at least February 2024.